Valuation: Agenus Inc.

Market Cap 32Cr 28Cr 26Cr 24Cr 45Cr 3.08TCr 45Cr 305.62Cr 119.76Cr 1.54TCr 120.85Cr 118.24Cr 5.13TCr P/E 2026 *
10.5x
P/E 2027 * -29.2x
Enterprise Value 32Cr 28Cr 26Cr 24Cr 45Cr 3.08TCr 45Cr 305.62Cr 119.76Cr 1.54TCr 120.85Cr 118.24Cr 5.13TCr EV / Sales 2026 *
2.29x
EV / Sales 2027 * 2.34x
Free-Float
93.77%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+4.27%
1 week+9.37%
Current month-0.40%
1 month+50.30%
3 months+136.39%
6 months+142.53%
Current year+137.90%
1 week 6.71
Extreme 6.71
7.47
1 month 4.94
Extreme 4.94
8.85
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
31.2
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/08/26 Free

Chief Executive Officer

19,71,500 4.4054%
05/08/26 Free

Director

50,000 0.1117%
05/08/26 Free

Director

50,000 0.1117%
Change 5-day change 1-year change 3-year change Capi.($)
+4.27%+9.37%+64.90%-74.59% 32Cr
-0.11%-1.67%+1.80%+19.90% 4.88TCr
+0.39%+3.48%+483.55%+618.11% 4.54TCr
+1.66%+2.27%+15.06%+90.32% 4.12TCr
+0.82%-0.40%+26.14%+13.50% 3.97TCr
-2.74%-2.74%+17.30%+56.10% 3.26TCr
+1.06%-1.53% - - 1.62TCr
-0.79%-1.95%+28.25%+137.78% 1.67TCr
-0.49%-0.34%+3.45%+29.14% 1.41TCr
-0.97%+0.53%+80.59%+42.53% 1.37TCr
Average +0.33%-0.49%+80.12%+103.64% 2.69TCr
Weighted average by Cap. +0.05%-0.84%+102.65%+152.09%

Financials

2026 *2027 *
Net sales 14Cr 12Cr 11Cr 10Cr 19Cr 1.34TCr 20Cr 133.21Cr 52Cr 672.07Cr 53Cr 52Cr 2.24TCr 14Cr 12Cr 11Cr 10Cr 19Cr 1.31TCr 19Cr 130.4Cr 51Cr 657.94Cr 52Cr 50Cr 2.19TCr
Net income 3.52Cr 3.04Cr 2.85Cr 2.6Cr 4.88Cr 336.56Cr 4.95Cr 33Cr 13Cr 168.62Cr 13Cr 13Cr 560.89Cr -2.61Cr -2.25Cr -2.11Cr -1.93Cr -3.62Cr -249.55Cr -3.67Cr -25Cr -9.71Cr -125.02Cr -9.8Cr -9.59Cr -415.89Cr
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
18/26/18 $7.460 +4.34% 2,87,508
17/26/17 $7.150 -2.32% 8,31,412
14/26/14 $7.320 +4.57% 12,51,966
13/26/13 $7.000 +1.45% 6,24,951
12/26/12 $6.900 +1.02% 11,54,187
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.150USD
Average target price
19.50USD
Spread / Average Target
+172.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock